Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Top Headlines

Pharmaceutical Business Review

AbbVie, Bristol-Myers to evaluate ABBV-399/Opdivo regimen in advanced solid tumors AbbVie will evaluate its investigational antibody drug conjugate, ABBV-399 (telisotuzumab vedotin), in combination with Bristol-Myers Squibb’s immunotheraphy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC). Contract Research & Services > Clinical Trials > News
SalvaRx, Immunova establish new JV firm Saugatuck Therapeutics By PBR Staff Writer
SalvaRx has signed an agreement with Immunova to create a new joint venture (JV) firm Saugatuck Therapeutics.
Drug Research > Drug Discovery & Development > News Landos Biopharma raises $10m in series A financing Landos Biopharma, an emerging biopharmaceutical company focused on developing improved treatments for autoimmune diseases, announced that it has raised $10m in a series A financing led by life sciences investment management firm Perceptive Advisors, which will serve as its exclusive investor for the Series A round.
Drug Research > Drug Discovery & Development > News Eleven Biotherapeutics completes Vicinium manufacturing for ongoing clinical trials in non-muscle invasive bladder cancer Eleven Biotherapeutics announced that it has completed the manufacturing of all Vicinium necessary for its ongoing Phase 3 registration trial in patients with non-muscle invasive bladder cancer (NMIBC), and for its cooperative research and development agreement (CRADA) with the National Cancer Institute.
Contract Research & Services > Clinical Trials > News
AbbVie, Bristol-Myers to evaluate ABBV-399/Opdivo regimen in advanced solid tumors By PBR Staff Writer
AbbVie will evaluate its investigational antibody drug conjugate, ABBV-399 (telisotuzumab vedotin), in combination with Bristol-Myers Squibb’s immunotheraphy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News Versartis’ phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint Versartis, an endocrine-focused biopharmaceutical firm that is developing somavaratan, a novel,aong-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), announced that the Velocity Phase 3 clinical trial of somavaratan in pediatric growth hormone deficiency (GHD) did not meet its primary endpoint of non-inferiority.
Contract Research & Services > Clinical Trials > News Merck, Pfizer get EC approval for skin cancer drug Bavencio By PBR Staff Writer
Merck and Pfizer have secured the approval of their skin cancer drug Bavencio (avelumab) from the European Commission (EC) as a monotherapy for the treatment of metastatic Merkel cell carcinoma (mMCC) in adults.
Regulatory Affairs > News

Latest News and Insight by Sector

Production & Manufacturing

Catalent to acquire Indiana-based CDMO Cook Pharmica for $950m
By PBR Staff Writer
Catalent has agreed to acquire Indiana-based contract development and manufacturing organization (CDMO) Cook Pharmica for $950m to consolidate its position in the bio-pharma sector.
Production & Manufacturing > Manufacturing > News
CHMP recommends GSK, Innoviva’s single inhaler triple therapy for COPD
By PBR Staff Writer
GlaxoSmithKline (GSK) and Innoviva announced that a committee of the European Medicines Agency (EMA) has adopted positive opinion for fluticasone furoate/ umeclidinium/vilanterol (FF/UMEC/VI) in treating chronic obstructive pulmonary disease (COPD) in adults.
Production & Manufacturing > Process & Production > News

Drug Research

SalvaRx, Immunova establish new JV firm Saugatuck Therapeutics
By PBR Staff Writer
SalvaRx has signed an agreement with Immunova to create a new joint venture (JV) firm Saugatuck Therapeutics.
Drug Research > Drug Discovery & Development > News
Landos Biopharma raises $10m in series A financing
Landos Biopharma, an emerging biopharmaceutical company focused on developing improved treatments for autoimmune diseases, announced that it has raised $10m in a series A financing led by life sciences investment management firm Perceptive Advisors, which will serve as its exclusive investor for the Series A round.
Drug Research > Drug Discovery & Development > News

Inward Investment

New WuXi Life Science to acquire WuXi PharmaTech for $3.3bn
Shanghai-based WuXi PharmaTech has entered into a merger agreement with New WuXi Life Science and its wholly owned subsidiary WuXi Merger, worth a total cash consideration of $3.3bn.
Inward Investment > News
PPF Group acquires minority stake in Cytune Pharma
By PBR Staff Writer
PPF Group, in cooperation with SOTIO has completed acquisition of minority stake in French biotechnology firm Cytune Pharma.
Inward Investment > News

Packaging

Catalent completes acquisition of Australia's Pharmapak
By PBR Staff Writer
US-based Catalent Pharma Solutions has strengthened its ability to provide integrated solutions to customers with the acquisition of Pharmapak Technologies, an Australian pharmaceutical packaging business.
Production & Manufacturing > OTC > News
MP Global Products introduces foam-free packaging for shipment of temperature sensitive pharmaceuticals
MP Global Thermal Packaging Products insulated protective mailers and box liners are specifically designed for temperature control and protection of mail order shipments of temperature sensitive pharma, pet meds, and natural and organic cosmetics.
Packaging > News

Contract Research & Services

Eleven Biotherapeutics completes Vicinium manufacturing for ongoing clinical trials in non-muscle invasive bladder cancer
Eleven Biotherapeutics announced that it has completed the manufacturing of all Vicinium necessary for its ongoing Phase 3 registration trial in patients with non-muscle invasive bladder cancer (NMIBC), and for its cooperative research and development agreement (CRADA) with the National Cancer Institute.
Contract Research & Services > Clinical Trials > News
AbbVie, Bristol-Myers to evaluate ABBV-399/Opdivo regimen in advanced solid tumors
By PBR Staff Writer
AbbVie will evaluate its investigational antibody drug conjugate, ABBV-399 (telisotuzumab vedotin), in combination with Bristol-Myers Squibb’s immunotheraphy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News

Automation

Broad Institute of MIT and Harvard joins discussions to create global CRISPR-Cas9 licensing pool
The Broad Institute of MIT and Harvard has joined discussions to form a non-exclusive CRISPR-Cas9 joint licensing pool coordinated by MPEG LA, an organization that operates patent pool licensing programs in various institutions and countries.
Automation > IT & Software > News
Servier, Transgene to apply viral vectorization technology to engineering of allogenic CAR-T
Servier and Transgene have signed a research agreement on the application of viral vectorization technology for the production of allogenic CAR-T cell therapies.
Automation > IT & Software > News

Regulatory Affairs

Merck, Pfizer get EC approval for skin cancer drug Bavencio
By PBR Staff Writer
Merck and Pfizer have secured the approval of their skin cancer drug Bavencio (avelumab) from the European Commission (EC) as a monotherapy for the treatment of metastatic Merkel cell carcinoma (mMCC) in adults.
Regulatory Affairs > News
Roche gets EC nod for Gazyvaro to treat advanced follicular lymphoma
By PBR Staff Writer
Roche has secured approval from the European Commission (EC) for its Gazyvaro (obinutuzumab) in combination with chemotherapy for the treatment for previously untreated advanced follicular lymphoma.
Regulatory Affairs > News



Data-Label.co.uk DataLabel have been supplying
the medical industry with labels
for over 10 years

Manufactures of
healthcare packaging
machinery